NCT06855225 2026-01-14A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinomaHoosier Cancer Research NetworkPhase 2 Not yet recruiting29 enrolled